Bristol Myers Squibb to Splash Out $475M on Dragonfly Immunotherapy
- Aug 17, 2020
- 2 min read
Bristol Myers Squibb is paying nearly half a billion dollars in up front and near-term payments to license an early-stage immunotherapy developed by Dragonfly Therapeutics, a firm that’s already a partner on potential treatments in oncology and other disease areas.
New York-based Bristol (NYSE: BMY), which inherited a relationship with the biotech when it acquired Celgene last year, announced terms of the new deal Monday.
Bristol plans a $475 million outlay for an exclusive global license to an investigational immunotherapy program focused on IL-12, an immune-stimulating protein, developed by the Waltham, MA-based firm. Dragonfly is also eligible for more payments, tied to development, regulatory and commercial milestones, plus royalties if Bristol commercializes any drugs as part of the collaboration. The companies didn’t disclosed the total value of the milestone payments.
The deal’s centerpiece is DF6002, a version of IL-12 that Dragonfly has engineered to last longer in the body. Dragonfly designed the drug candidate, a type of protein known as a cytokine, to make it easier for the immune system to attack tumors by changing the composition of the tumor microenvironment—the complex mixture of cells, blood vessels, and more that surrounds cancer cells and interacts with them in ways that impacts their growth. Prolonging the cytokine’s biological activity is intended to improve its anti-tumor effects.
The FDA cleared Dragonfly to begin human tests of DF6002 in May; a month ago the company announced it had dosed its first patient in a Phase 1/2 study evaluating the drug by itself as well in combination with another immunotherapy, a so-called checkpoint inhibitor designed to block the PD-1 pathway, in patients with solid tumors. Dragonfly co-founder and CEO Bill Haney, in a prepared statement, said the partnership with Bristol makes particular sense given the larger company’s range of cancer drugs.
Bristol plans to evaluate DF6002 as a potential treatment for cancers and blood disorders. Under the deal terms the New York pharma takes on responsibility for the development and commercialization of that drug candidate plus any related products.
Engineered cytokines are also an area of interest for other biopharmas. Sanofi (NASDAQ: SNY) spent $2.5 billion on Synthorx, a San Diego biotech, in December for its immunotherapies, including an engineered version of another cytokine, IL-2.
The Dragonfly IL-12 drug is the second candidate the biotech has brought into clinical testing. Last fall the company began a Phase 1/2 study of its most advanced immunotherapy in patients with solid tumors that express human epidermal growth factor receptor 2, a protein better known as HER2. That potential treatment is based on natural killer cells, which are the focus of the initial partnership that Bristol inherited from Celgene. Read more about Dragonfly’s origins, partnerships, and previous work with Bristol.
Nice , A significant investment in innovative immunotherapy research highlights the growing importance of advanced healthcare solutions and the future potential of biotechnology. Developments like this demonstrate how strategic partnerships, scientific innovation, and careful planning can contribute to major breakthroughs in medical treatments. For students exploring healthcare management, biotechnology, and strategic risk analysis, Risk Management Assignment Help UK can provide valuable academic guidance in understanding complex projects and decision-making processes. Thank you for sharing this insightful update on the evolving landscape of medical innovation.
This is truly exciting news for the future of cancer treatment! Bristol Myers Squibb's $475M investment in Dragonfly's IL-12 immunotherapy shows just how seriously the medical world is taking immune system-based approaches to fighting disease. What's fascinating is that DF6002 works by enhancing the body's natural ability to attack tumors — a reminder of how powerful our immune system really is when properly supported. It makes you think about immune health from every angle, including everyday habits. Many people wonder, Is It Good to Take a Multivitamin Every Day — and while a daily multivitamin certainly can't replace groundbreaking therapies like this, maintaining baseline nutritional support keeps your immune system primed and functioning well. Innovations like Dragonfly's engineered cytokine platform…
The part that caught my attention was the scale of Bristol Myers Squibb’s investment and what it suggests about the confidence being placed in Dragonfly’s immunotherapy research. It’s always interesting to see how partnerships and acquisitions in biotechnology are often driven by the potential of treatments that are still developing, yet already generating significant interest across the industry. I found myself wondering which aspect of the immunotherapy platform was considered the biggest factor behind the $475 million commitment, since those decisions usually reflect years of scientific progress rather than a single breakthrough. Reading about developments like this reminds me a bit of how people search for resources such as Best HND Assignment Help, where the real value often comes from…
Reading this blog about the Bristol Myers Squibb–Dragonfly immunotherapy collaboration really shows how fast biotech innovation is moving and how big pharma is actively investing in next-generation immune therapies. It’s exciting to see science and partnerships shaping future cancer treatments, but it also reminds us how important it is to balance modern innovation with everyday wellness. Alongside breakthroughs like this, people are becoming more aware of lifestyle-driven health choices, especially for immunity and digestion. That’s where ReVeda fits in, supporting a more holistic approach to wellbeing. Many users today are also exploring How To Improve Your Gut Health through simple dietary habits and supplements that work with the body naturally. In India, the rising interest in Gut Health Gummies In…
This is really exciting news! It’s impressive to see Bristol-Myers Squibb investing so heavily in Dragonfly’s immunotherapy work. Innovations like this could have a huge impact on future treatments and show how much potential there is in developing cutting-edge therapies. It’s inspiring to see companies pushing the boundaries of medical research and investing in solutions that could help so many people.
For students and professionals trying to keep up with fast-moving industries like biotech while managing other responsibilities, it can be overwhelming. That’s why resources like assignment help Oxford can be really helpful, allowing people to stay on top of their academic work while keeping up with developments in fields that interest them.